Is IMDX or MBAI more undervalued in 2026?

CirclFi compares Insight Molecular Diagnostics I (IMDX) and Check-Cap Ltd. (MBAI) using 13 institutional-grade valuation models. IMDX has a Quality of Company score of 5.3/10 while MBAI scores 2.5/10.

Which is a better buy — IMDX or MBAI?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do IMDX and MBAI valuations compare?

IMDX at $6.53 and MBAI at $1.74 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

IMDX vs MBAI Valuation Comparison 2026 — Intrinsic Value Analysis

IMDX

Diagnostics & Research

Insight Molecular Diagnostics I

Quality

5.3

out of 10

Value Trap

SAFE

Price

$6.53

Last close

Models

10/13

Active

MBAI

Diagnostics & Research

Check-Cap Ltd.

Quality

2.5

out of 10

Value Trap

—

Price

$1.74

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	IMDX Fair Value	IMDX Upside	MBAI Fair Value	MBAI Upside
Bayesian DCF	Intrinsic	$2.19	-66.5%	$0.46	-73.5%
Earnings Power Value	Intrinsic	$1.19	-71.6%	$5.91	+307.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for IMDX vs MBAI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IMDX vs MBAI — Which Stock Is More Undervalued?

IMDX scores higher with a 5.3/10 quality rating vs MBAI's 2.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Insight Molecular Diagnostics I (IMDX) and Check-Cap Ltd. (MBAI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IMDX currently trades at $6.53 with a QOC of 5.3/10, while MBAI trades at $1.74 with a QOC of 2.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).